Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.60 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274365 | 1.00 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL274149 | 0.88 | HTR7 (1.00) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL764077 | 0.86 | HTR2A (0.65) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| SCHEMBL3713285 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL30274410 | 0.86 | HTR7 (0.83) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL23875880 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL23875899 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL3709723 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL6089057 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL6088731 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| WO-2021195603-A1 | ANTI-MALARIAL COMPOUNDS AND USES THEREOF | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY (US) | 2021-09-30 | — | — | WO | disclosed |
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | PTC THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3718405-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2434891-B1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| CN-108218864-B | A kind of green synthesis method of tetrahydro-beta-carboline heterocyclic compound | 温州大学 | 2019-08-27 | — | — | CN | disclosed |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| CN-108218864-A | A kind of green synthesis method of tetrahydro-beta-carboline heterocyclic compound | 温州大学 | 2018-06-29 | — | — | CN | disclosed |
| US-8697662-B2 | Methods for treating Kaposi sarcoma | PTC THERAPEUTICS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20120202801-A1 | METHODS FOR TREATING BREAST CANCER | PTC THERAPEUTICS, INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | PTC THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157401-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-6720331-B2 | HAVING ANTI-MITOTIC ACTIVITY FOR THERAPY OF CANCER | NATIONAL SUN YAT-SEN UNIVERSITY (TW) | 2004-04-13 | — | — | US | disclosed |
| US-20030040527-A1 | 1-substituted 1,2,3,4-tetrahydro-beta-carboline and 3,4-dihydro-beta-carboline and analogs as antitumor agents | NATIONAL SUN YAT-SEN UNIVERSITY (TW) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | HDGF, VEGFA, FLT4 | HTR7 1580/4885CYP3A4 4761/4885CYP2D6 4842/4885 |
| US-20030040527-A1 | 1-substituted 1,2,3,4-tetrahydro-beta-carboline and 3,4-dihydro-beta-carboline and analogs as antitumor agents | DCK, CCR1, CCNT1 | HTR7 928/4885CYP3A4 524/4885CYP2D6 110/4885 |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | HTR7 4366/4885CYP3A4 4614/4885CYP2D6 4809/4885 |
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | HTR7 4356/4885CYP3A4 4613/4885CYP2D6 4803/4885 |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | HTR7 4356/4885CYP3A4 4613/4885CYP2D6 4803/4885 |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | SARS1, POLRMT, EIF2AK2 | HTR7 4102/4885CYP3A4 2221/4885CYP2D6 3664/4885 |
| US-20120157401-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | VHL, NGF, VEGFA | HTR7 3489/4885CYP3A4 4879/4885CYP2D6 4864/4885 |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | EIF2AK2, POLRMT, POLM | HTR7 4338/4885CYP3A4 4400/4885CYP2D6 4700/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | HTR7 3935/4885CYP3A4 3112/4885CYP2D6 4147/4885 |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | HDGF, HIF1AN, VEGFA | HTR7 4420/4885CYP3A4 4485/4885CYP2D6 4660/4885 |
| US-20120202801-A1 | METHODS FOR TREATING BREAST CANCER | VEGFA, FLT4, FLT1 | HTR7 2821/4885CYP3A4 4548/4885CYP2D6 4792/4885 |
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | ACP3, BPHL, PTGFR | HTR7 1813/4885CYP3A4 3553/4885CYP2D6 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.